NHS
First approved C5 complement inhibitor recommended by NICE for NHS use
April 15, 2021NHS, NICE
NICE has recommended Ultomiris (ravulizumab) for use in the NHS for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult …
The Truth Behind the £1.8 Million Drug
March 31, 2021Manufacturing and Production FDA, NHS, NICE
As NICE approves the most expensive drug ever for use by the NHS, Jack Goddard takes a look at drug …
NHS agrees on MSD interim colorectal cancer treatment
March 25, 2021COVID-19, Cancer, MSD, NHS
MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …
AstraZeneca leukaemia treatment recommended for NHS use
March 18, 2021AstraZeneca, NHS
AstraZeneca has announced today that its oral targeted cancer therapy, Calquence (acalabrutinib), has been recommended by NICE for routine use …
NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations
December 8, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …
NICE recommends Lilly’s Emgality for chronic and episodic migraine
November 18, 2020Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK
Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …
NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura
November 12, 2020Sales and Marketing NHS, NICE, Sanofi, pharma
Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …
NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia
November 10, 2020Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax
NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …
NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer
November 5, 2020Sales and Marketing BMS, Cancer, NHS, NICE, opdivo
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …
NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
October 22, 2020Sales and Marketing MSD, NCIE, NHS, keytruda
NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …
Bavencio/axitinib combo approved for NHS Scotland in advanced renal cell carcinoma
October 13, 2020Manufacturing and Production, Sales and Marketing Merck, NHS, Pfizer, SMC
The Scottish Medicines Consortium (SMC) has given the go-ahead to Merck KGaA and Pfizer’s combination of their PD-L1 inhibitor immunotherapy …
NICE gives go-ahead for Sandoz’s Rizmoic to treat opioid-induced constipation
September 30, 2020Research and Development, Sales and Marketing NHS, NICE, Rizmoic, Sandoz, UK
The National Institute for Health and Care Excellence (NICE) has recommended Sandoz’s Rizmoic (naldemedine) for the treatment of opioid-induced constipation …
Alexion’s Ondexxya approved for NHS Scotland to treat uncontrolled and life-threatening bleeds
September 9, 2020Research and Development, Sales and Marketing Alexion, NHS, Ondexxya, Scotland, nhs scotland
The Scottish Medicines Consortium (SMC) has given its recommendation to Alexion’s Ondexxya (andexanet alfa) to routine use on NHS Scotland …
NICE to recommend Roche cancer treatment
June 26, 2020Medical Communications NHS, NICE
NICE are set to recommend Roche’s Rozlytrek (Entrectinib) cancer treatment which will be the second histology drug to be recommended …
NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps
June 25, 2020Sales and Marketing Mayzent, NHS, NICE, Novartis
Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …
